Two new large observational studies show GLP-1 drugs are associated with reduced dementia in people with diabetes.

The Swedish study included 88,381 participants. The researchers found that people taking GLP-1 agonists had a 31% lower risk of developing dementia compared to those taking sulfonylureas, and a 23% lower risk compared to those taking DPP-4 inhibitors. These findings were consistent in various sensitivity analyses.

The US study included a total of 89,074 Medicare beneficiaries. Conclusion: New use of GLP-1RAs was significantly associated with a lower risk of PD compared to new use of DPP4i in a large cohort of older adults with T2D.

“Very promising” said Sara Hagg, who lead the Swedish study.

First study link:

https://lnkd.in/dZaNp4Wy

Second study link:

https://lnkd.in/dc6K5xxD